Stay updated on BIBF 1120 Long-Term Safety in Idiopathic Pulmonary Fibrosis Clinical Trial
Sign up to get notified when there's something new on the BIBF 1120 Long-Term Safety in Idiopathic Pulmonary Fibrosis Clinical Trial page.

Latest updates to the BIBF 1120 Long-Term Safety in Idiopathic Pulmonary Fibrosis Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays the completed Phase 3 extension study of nintedanib for idiopathic pulmonary fibrosis, including its eligibility criteria, safety outcome, study locations, and record history.SummaryDifference100%

- Check8 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check15 days agoChange DetectedA sitewide NIH notice announces a transition from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check22 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page, while the study record remains unavailable.SummaryDifference0.2%

- Check28 days agoChange DetectedThe displayed site revision changes from v3.7.0 to v3.7.1 while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe page now renders a 403 Forbidden error for the study NCT01619085, showing the 403 message and a Home link, replacing the previous study record content.SummaryDifference16%

Stay in the know with updates to BIBF 1120 Long-Term Safety in Idiopathic Pulmonary Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BIBF 1120 Long-Term Safety in Idiopathic Pulmonary Fibrosis Clinical Trial page.